Published in JAMA on April 21, 1999
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry (2002) 1.62
PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol (2009) 1.61
The cholinergic system and Parkinson disease. Behav Brain Res (2010) 1.38
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 1.36
Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev (2009) 1.33
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci (2015) 1.26
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.18
Septohippocampal acetylcholine: involved in but not necessary for learning and memory? Learn Mem (2004) 1.17
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol (2011) 1.13
Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One (2009) 1.12
Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging (2007) 1.06
Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 1.05
The apolipoprotein E gene, attention, and brain function. Neuropsychology (2002) 1.05
Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology (2011) 1.02
Cholinergic modulation of hippocampal network function. Front Synaptic Neurosci (2013) 1.01
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology (2011) 1.00
Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. J Alzheimers Dis (2009) 0.98
Production of the Acetylcholinesterase Inhibitor from Yarrowia lipolytica S-3. Mycobiology (2008) 0.97
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep (2013) 0.95
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol (2011) 0.94
Melatonin in Alzheimer's disease. Int J Mol Sci (2013) 0.92
Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol Dis (2014) 0.91
Sensory evoked and event related oscillations in Alzheimer's disease: a short review. Cogn Neurodyn (2010) 0.91
MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol Aging (2009) 0.90
A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra (2011) 0.90
Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocr Disord (2010) 0.89
Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience (2015) 0.89
The prominent role of stimulus processing: cholinergic function and dysfunction in cognition. Curr Opin Neurol (2011) 0.88
Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Alzheimer's disease. Dialogues Clin Neurosci (2000) 0.86
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials (2009) 0.86
The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr (2011) 0.86
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 0.86
Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosci (2009) 0.85
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr (2013) 0.85
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol (2005) 0.85
Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease [corrected]. PLoS One (2013) 0.85
A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry (2006) 0.85
Cholinergic modulation of visual working memory during aging: a parametric PET study. Brain Res Bull (2009) 0.84
Dementia with Lewy bodies. Neurol Clin (2007) 0.83
Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. J Comp Neurol (2014) 0.83
Abnormal short latency afferent inhibition in early Alzheimer's disease: a transcranial magnetic demonstration. J Neural Transm (Vienna) (2008) 0.83
Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. J Alzheimers Dis (2007) 0.83
Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiol Aging (2011) 0.83
Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol (2002) 0.83
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. BMC Neurol (2014) 0.82
The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimers Dement (2014) 0.82
Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis? Mol Neurodegener (2010) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther (2013) 0.81
Cholinesterase inhibitors affect brain potentials in amnestic mild cognitive impairment. Brain Res (2007) 0.80
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging (2011) 0.80
GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity. J Biol Chem (2010) 0.80
Therapeutic approaches to age-associated neurocognitive disorders. Dialogues Clin Neurosci (2001) 0.79
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A national registry on aging. Alzheimers Dement (2009) 0.78
Impaired Cholinergic Excitation of Prefrontal Attention Circuitry in the TgCRND8 Model of Alzheimer's Disease. J Neurosci (2015) 0.78
Challenging the cholinergic hypothesis in Alzheimer disease. JAMA (1999) 0.78
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Neurol Sci (2016) 0.77
Cholinergic markers in Alzheimer disease. JAMA (1999) 0.77
Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates. Nucl Med Biol (2015) 0.77
Cognitive aging and Alzheimer's disease. Postgrad Med J (2005) 0.77
PET Radioligands for Imaging of Tau Pathology: Current Status. Nucl Med Mol Imaging (2015) 0.76
Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging (2016) 0.76
The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr (2015) 0.75
Age-dependent biochemical dysfunction in skeletal muscle of triple-transgenic mouse model of Alzheimer`s disease. Curr Alzheimer Res (2015) 0.75
Cholinergic neurons-keeping check on amyloid β in the cerebral cortex. Front Cell Neurosci (2013) 0.75
Brain aging research at the close of the 20th century: from bench to bedside. Dialogues Clin Neurosci (2001) 0.75
Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study. Prim Care Companion J Clin Psychiatry (2008) 0.75
Intraneuronal amyloid-β accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration. Brain (2015) 0.75
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimers Res Ther (2016) 0.75
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease. J Huntingtons Dis (2016) 0.75
Immunization Against Specific Fragments of Neurotrophin p75 Receptor Protects Forebrain Cholinergic Neurons in the Olfactory Bulbectomized Mice. J Alzheimers Dis (2016) 0.75
T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. Sci Rep (2015) 0.75
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology (1994) 5.81
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med (1998) 4.43
Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med (1974) 4.10
Intraneuronal Abeta42 accumulation in human brain. Am J Pathol (2000) 3.83
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology (2003) 3.62
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A (1998) 2.91
A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci U S A (1999) 2.81
Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet (1995) 2.66
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science (1980) 2.45
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry (1994) 2.41
Tei-index in patients with mild-to-moderate congestive heart failure. Eur Heart J (2000) 2.37
Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol (1992) 2.19
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
The pathology of Legionnaires' disease. Fourteen fatal cases from the 1977 outbreak in Vermont. Arch Pathol Lab Med (1978) 2.06
Rising mortality from motoneuron disease in the USA, 1962-84. Lancet (1989) 2.05
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol (1999) 2.02
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry (2000) 1.93
Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J Periodontal Res (1999) 1.90
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology (2006) 1.89
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry (1994) 1.84
The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull (1983) 1.81
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry (1986) 1.80
Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry (1989) 1.79
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology (2009) 1.78
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol (1995) 1.69
Collagenolytic activity associated with Bacteroides species and Actinobacillus actinomycetemcomitans. J Periodontal Res (1982) 1.69
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science (1982) 1.63
Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry (1999) 1.62
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry (2006) 1.62
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry (1998) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol (1989) 1.57
Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol (1990) 1.56
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
Investigation of a fatality from nonoccupational aluminum phosphide exposure: measurement of aluminum in tissue and body fluids as a marker of exposure. J Lab Clin Med (1993) 1.53
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry (1996) 1.52
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry (1997) 1.51
Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol (1978) 1.50
Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol (1988) 1.49
The development and piloting of a capacity assessment tool. J Clin Ethics (2001) 1.48
The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry (1995) 1.46
The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry (1997) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res (1992) 1.45
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem (1995) 1.41
Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology (2008) 1.41
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
Precise determination of the unperturbed 8B neutrino spectrum. Phys Rev Lett (2012) 1.39
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry (1998) 1.39
A 50-year-old male with diabetes mellitus, peripheral neuropathy, hypothyroidism, obesity, sleep disorder, pickwickian syndrome, and heart failure. Mt Sinai J Med (1998) 1.38
Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol (1992) 1.38
Elevated cortical zinc in Alzheimer disease. Neurology (2006) 1.38
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry (1999) 1.36
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Anomalous origin of both vertebral arteries. Clin Anat (1999) 1.35
Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol (1992) 1.33
Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology (1988) 1.32
The ionic permeability changes during acetylcholine-induced responses of Aplysia ganglion cells. J Gen Physiol (1968) 1.29
Physiologic factors in the selection of patients for superficial temporal artery-to-middle cerebral artery anastomosis. Surgery (1974) 1.28